GSK Gsk Plc

1,654.50

3.50 (0.21%)

Last Updated: 12:46:15

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Gsk Plc	LSE:GSK	London	Ordinary Share	GB00BN7SWP63	ORD 31 1/4P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	3.50	0.21%	1,654.50	1,654.00	1,655.00	1,661.50	1,650.00	1,656.50	772,127	12:46:15

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	30.33B	4.93B	1.1970	13.83	68.16B

GlaxoSmithKline: Submits New Drug Application to US Regulator for HIV Treatment

18/10/2018 4:51pm

Dow Jones News

Gsk (LSE:GSK)
Historical Stock Chart

From Apr 2019 to Apr 2024

By Maryam Cockar

GlaxoSmithKline PLC (GSK.LN) said Thursday that its subsidiary, ViiV Healthcare Ltd., has submitted a new drug application to the U.S. Food & Drug Administration for its HIV treatment.

The new drug application to the US regulator is for a single-tablet, two-drug regimen of Dolutegravir and Lamivudine for the treatment of HIV-1 infection.

In September Viiv Healthcare submitted a marketing authorization application to the European Medicines Agency for Dolutegravir and Lamivudine as a single-tablet, two-drug regimen for HIV and the company expects approval in the coming months.

ViiV Healthcare is majority owned by GSK, with Pfizer Inc. (PFE) and Shionogi & Co. Ltd. (4507.TO)

At 1513 GMT, GSK shares were up 20.20 pence, or 1.4%, at 1514.60

Write to Maryam Cockar at maryam.cockar@dowjones.com

(END) Dow Jones Newswires

October 18, 2018 11:36 ET (15:36 GMT)